Utility of tumor markers in determining resectability of pancreatic cancer

Michael G. Schlieman, Hung S Ho, Richard J Bold, L. William Traverso, Sherry Wren, Lygia Stewart, Carlos A. Pellegrini

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Hypothesis: Despite advances in preoperative radiologic imaging, a significant fraction of potentially resectable pancreatic cancers are found to be unresectable at laparotomy. We tested the hypothesis that preoperative serum levels of CA19-9 (cancer antigen) and carcinoembryonic antigen will identify patients with unresectable pancreatic cancer despite radiologic staging demonstrating resectable disease. Design and Setting: Academic tertiary care referral center. Patients: From March 1, 1996, to July 31, 2002, 125 patients were identified who underwent surgical exploration for potentially resectable pancreatic cancer based on a preoperative computed tomographic scan; in 89 of them a preoperative tumor marker had been measured. Main Outcome Measures: Preoperative tumor markers (CA19-9 and carcinoembryonic antigen) were correlated with extent of disease at exploration. As CA19-9 is excreted in the biliary system, CA19-9 adjusted for the degree of hyperbilirubinemia was determined and analyzed. Results: Of the 89 patients, 40 (45%) had localized disease and underwent resection, 25 (28%) had locally advanced (unresectable) disease, and 24 (27%) had metastatic disease. The mean adjusted CA19-9 level was significantly lower in those with localized disease than those with locally advanced (63 vs 592; P=.003) or metastatic (63 vs 1387; P<.001) disease. When a threshold adjusted CA19-9 level of 150 was used, the positive predictive value for determination of unresectable disease was 88%. Carcinoembryonic antigen level was not correlated with extent of disease. Conclusions: Among the patients with resectable pancreatic cancer based on preoperative imaging studies, those with abnormally high serum levels of CA19-9 may have unresectable disease. These patients may benefit from additional staging modalities such as diagnostic laparoscopy to avoid unnecessary laparotomy.

Original languageEnglish (US)
Pages (from-to)951-956
Number of pages6
JournalArchives of Surgery
Volume138
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

Tumor Biomarkers
Pancreatic Neoplasms
Carcinoembryonic Antigen
Tertiary Care Centers
Laparotomy
Hyperbilirubinemia
Biliary Tract
Serum
Laparoscopy
Outcome Assessment (Health Care)
Antigens

ASJC Scopus subject areas

  • Surgery

Cite this

Schlieman, M. G., Ho, H. S., Bold, R. J., Traverso, L. W., Wren, S., Stewart, L., & Pellegrini, C. A. (2003). Utility of tumor markers in determining resectability of pancreatic cancer. Archives of Surgery, 138(9), 951-956. https://doi.org/10.1001/archsurg.138.9.951

Utility of tumor markers in determining resectability of pancreatic cancer. / Schlieman, Michael G.; Ho, Hung S; Bold, Richard J; Traverso, L. William; Wren, Sherry; Stewart, Lygia; Pellegrini, Carlos A.

In: Archives of Surgery, Vol. 138, No. 9, 01.09.2003, p. 951-956.

Research output: Contribution to journalArticle

Schlieman, MG, Ho, HS, Bold, RJ, Traverso, LW, Wren, S, Stewart, L & Pellegrini, CA 2003, 'Utility of tumor markers in determining resectability of pancreatic cancer', Archives of Surgery, vol. 138, no. 9, pp. 951-956. https://doi.org/10.1001/archsurg.138.9.951
Schlieman, Michael G. ; Ho, Hung S ; Bold, Richard J ; Traverso, L. William ; Wren, Sherry ; Stewart, Lygia ; Pellegrini, Carlos A. / Utility of tumor markers in determining resectability of pancreatic cancer. In: Archives of Surgery. 2003 ; Vol. 138, No. 9. pp. 951-956.
@article{a3223b9952db42888a2f70dd655e315a,
title = "Utility of tumor markers in determining resectability of pancreatic cancer",
abstract = "Hypothesis: Despite advances in preoperative radiologic imaging, a significant fraction of potentially resectable pancreatic cancers are found to be unresectable at laparotomy. We tested the hypothesis that preoperative serum levels of CA19-9 (cancer antigen) and carcinoembryonic antigen will identify patients with unresectable pancreatic cancer despite radiologic staging demonstrating resectable disease. Design and Setting: Academic tertiary care referral center. Patients: From March 1, 1996, to July 31, 2002, 125 patients were identified who underwent surgical exploration for potentially resectable pancreatic cancer based on a preoperative computed tomographic scan; in 89 of them a preoperative tumor marker had been measured. Main Outcome Measures: Preoperative tumor markers (CA19-9 and carcinoembryonic antigen) were correlated with extent of disease at exploration. As CA19-9 is excreted in the biliary system, CA19-9 adjusted for the degree of hyperbilirubinemia was determined and analyzed. Results: Of the 89 patients, 40 (45{\%}) had localized disease and underwent resection, 25 (28{\%}) had locally advanced (unresectable) disease, and 24 (27{\%}) had metastatic disease. The mean adjusted CA19-9 level was significantly lower in those with localized disease than those with locally advanced (63 vs 592; P=.003) or metastatic (63 vs 1387; P<.001) disease. When a threshold adjusted CA19-9 level of 150 was used, the positive predictive value for determination of unresectable disease was 88{\%}. Carcinoembryonic antigen level was not correlated with extent of disease. Conclusions: Among the patients with resectable pancreatic cancer based on preoperative imaging studies, those with abnormally high serum levels of CA19-9 may have unresectable disease. These patients may benefit from additional staging modalities such as diagnostic laparoscopy to avoid unnecessary laparotomy.",
author = "Schlieman, {Michael G.} and Ho, {Hung S} and Bold, {Richard J} and Traverso, {L. William} and Sherry Wren and Lygia Stewart and Pellegrini, {Carlos A.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1001/archsurg.138.9.951",
language = "English (US)",
volume = "138",
pages = "951--956",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Utility of tumor markers in determining resectability of pancreatic cancer

AU - Schlieman, Michael G.

AU - Ho, Hung S

AU - Bold, Richard J

AU - Traverso, L. William

AU - Wren, Sherry

AU - Stewart, Lygia

AU - Pellegrini, Carlos A.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Hypothesis: Despite advances in preoperative radiologic imaging, a significant fraction of potentially resectable pancreatic cancers are found to be unresectable at laparotomy. We tested the hypothesis that preoperative serum levels of CA19-9 (cancer antigen) and carcinoembryonic antigen will identify patients with unresectable pancreatic cancer despite radiologic staging demonstrating resectable disease. Design and Setting: Academic tertiary care referral center. Patients: From March 1, 1996, to July 31, 2002, 125 patients were identified who underwent surgical exploration for potentially resectable pancreatic cancer based on a preoperative computed tomographic scan; in 89 of them a preoperative tumor marker had been measured. Main Outcome Measures: Preoperative tumor markers (CA19-9 and carcinoembryonic antigen) were correlated with extent of disease at exploration. As CA19-9 is excreted in the biliary system, CA19-9 adjusted for the degree of hyperbilirubinemia was determined and analyzed. Results: Of the 89 patients, 40 (45%) had localized disease and underwent resection, 25 (28%) had locally advanced (unresectable) disease, and 24 (27%) had metastatic disease. The mean adjusted CA19-9 level was significantly lower in those with localized disease than those with locally advanced (63 vs 592; P=.003) or metastatic (63 vs 1387; P<.001) disease. When a threshold adjusted CA19-9 level of 150 was used, the positive predictive value for determination of unresectable disease was 88%. Carcinoembryonic antigen level was not correlated with extent of disease. Conclusions: Among the patients with resectable pancreatic cancer based on preoperative imaging studies, those with abnormally high serum levels of CA19-9 may have unresectable disease. These patients may benefit from additional staging modalities such as diagnostic laparoscopy to avoid unnecessary laparotomy.

AB - Hypothesis: Despite advances in preoperative radiologic imaging, a significant fraction of potentially resectable pancreatic cancers are found to be unresectable at laparotomy. We tested the hypothesis that preoperative serum levels of CA19-9 (cancer antigen) and carcinoembryonic antigen will identify patients with unresectable pancreatic cancer despite radiologic staging demonstrating resectable disease. Design and Setting: Academic tertiary care referral center. Patients: From March 1, 1996, to July 31, 2002, 125 patients were identified who underwent surgical exploration for potentially resectable pancreatic cancer based on a preoperative computed tomographic scan; in 89 of them a preoperative tumor marker had been measured. Main Outcome Measures: Preoperative tumor markers (CA19-9 and carcinoembryonic antigen) were correlated with extent of disease at exploration. As CA19-9 is excreted in the biliary system, CA19-9 adjusted for the degree of hyperbilirubinemia was determined and analyzed. Results: Of the 89 patients, 40 (45%) had localized disease and underwent resection, 25 (28%) had locally advanced (unresectable) disease, and 24 (27%) had metastatic disease. The mean adjusted CA19-9 level was significantly lower in those with localized disease than those with locally advanced (63 vs 592; P=.003) or metastatic (63 vs 1387; P<.001) disease. When a threshold adjusted CA19-9 level of 150 was used, the positive predictive value for determination of unresectable disease was 88%. Carcinoembryonic antigen level was not correlated with extent of disease. Conclusions: Among the patients with resectable pancreatic cancer based on preoperative imaging studies, those with abnormally high serum levels of CA19-9 may have unresectable disease. These patients may benefit from additional staging modalities such as diagnostic laparoscopy to avoid unnecessary laparotomy.

UR - http://www.scopus.com/inward/record.url?scp=0042418394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042418394&partnerID=8YFLogxK

U2 - 10.1001/archsurg.138.9.951

DO - 10.1001/archsurg.138.9.951

M3 - Article

C2 - 12963650

AN - SCOPUS:0042418394

VL - 138

SP - 951

EP - 956

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 9

ER -